5,399 results on '"Prodromal Symptoms"'
Search Results
2. Sex-dependent interactions between prodromal intestinal inflammation and LRRK2 G2019S in mice promote endophenotypes of Parkinsons disease.
- Author
-
Fang, Ping, Yu, Lewis, Espey, Hannah, Agirman, Gulistan, Kazmi, Sabeen, Li, Kai, Deng, Yongning, Lee, Jamie, Hrncir, Haley, Romero-Lopez, Arlene, Arnold, Arthur, and Hsiao, Elaine
- Subjects
Animals ,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 ,Parkinson Disease ,Mice ,Male ,Female ,Endophenotypes ,alpha-Synuclein ,Prodromal Symptoms ,Disease Models ,Animal ,Mice ,Transgenic ,Humans ,Sex Factors ,Inflammation ,Mice ,Inbred C57BL ,Sex Characteristics - Abstract
Gastrointestinal (GI) disruptions and inflammatory bowel disease (IBD) are commonly associated with Parkinsons disease (PD), but how they may impact risk for PD remains poorly understood. Herein, we provide evidence that prodromal intestinal inflammation expedites and exacerbates PD endophenotypes in rodent carriers of the human PD risk allele LRRK2 G2019S in a sex-dependent manner. Chronic intestinal damage in genetically predisposed male mice promotes α-synuclein aggregation in the substantia nigra, loss of dopaminergic neurons and motor impairment. This male bias is preserved in gonadectomized males, and similarly conferred by sex chromosomal complement in gonadal females expressing human LRRK2 G2019S. The early onset and heightened severity of neuropathological and behavioral outcomes in male LRRK2 G2019S mice is preceded by increases in α-synuclein in the colon, α-synuclein-positive macrophages in the colonic lamina propria, and loads of phosphorylated α-synuclein within microglia in the substantia nigra. Taken together, these data reveal that prodromal intestinal inflammation promotes the pathogenesis of PD endophenotypes in male carriers of LRRK2 G2019S, through mechanisms that depend on genotypic sex and involve early accumulation of α-synuclein in myeloid cells within the gut.
- Published
- 2024
3. Using brain structural neuroimaging measures to predict psychosis onset for individuals at clinical high-risk.
- Author
-
Zhu, Yinghan, Maikusa, Norihide, Radua, Joaquim, Sämann, Philipp, Fusar-Poli, Paolo, Agartz, Ingrid, Andreassen, Ole, Bachman, Peter, Baeza, Inmaculada, Chen, Xiaogang, Choi, Sunah, Corcoran, Cheryl, Ebdrup, Bjørn, Fortea, Adriana, Garani, Ranjini, Glenthøj, Birte, Glenthøj, Louise, Haas, Shalaila, Hamilton, Holly, Hayes, Rebecca, He, Ying, Heekeren, Karsten, Kasai, Kiyoto, Katagiri, Naoyuki, Kim, Minah, Kristensen, Tina, Kwon, Jun, Lawrie, Stephen, Lebedeva, Irina, Lee, Jimmy, Loewy, Rachel, Mathalon, Daniel, McGuire, Philip, Mizrahi, Romina, Mizuno, Masafumi, Møller, Paul, Nemoto, Takahiro, Nordholm, Dorte, Omelchenko, Maria, Raghava, Jayachandra, Røssberg, Jan, Rössler, Wulf, Salisbury, Dean, Sasabayashi, Daiki, Smigielski, Lukasz, Sugranyes, Gisela, Takahashi, Tsutomu, Tamnes, Christian, Tang, Jinsong, Theodoridou, Anastasia, Tomyshev, Alexander, Uhlhaas, Peter, Værnes, Tor, van Amelsvoort, Therese, Waltz, James, Westlye, Lars, Zhou, Juan, Thompson, Paul, Hernaus, Dennis, Jalbrzikowski, Maria, and Koike, Shinsuke
- Subjects
Humans ,Psychotic Disorders ,Magnetic Resonance Imaging ,Male ,Female ,Brain ,Neuroimaging ,Adult ,Young Adult ,Machine Learning ,Adolescent ,Prodromal Symptoms - Abstract
Machine learning approaches using structural magnetic resonance imaging (sMRI) can be informative for disease classification, although their ability to predict psychosis is largely unknown. We created a model with individuals at CHR who developed psychosis later (CHR-PS+) from healthy controls (HCs) that can differentiate each other. We also evaluated whether we could distinguish CHR-PS+ individuals from those who did not develop psychosis later (CHR-PS-) and those with uncertain follow-up status (CHR-UNK). T1-weighted structural brain MRI scans from 1165 individuals at CHR (CHR-PS+, n = 144; CHR-PS-, n = 793; and CHR-UNK, n = 228), and 1029 HCs, were obtained from 21 sites. We used ComBat to harmonize measures of subcortical volume, cortical thickness and surface area data and corrected for non-linear effects of age and sex using a general additive model. CHR-PS+ (n = 120) and HC (n = 799) data from 20 sites served as a training dataset, which we used to build a classifier. The remaining samples were used external validation datasets to evaluate classifier performance (test, independent confirmatory, and independent group [CHR-PS- and CHR-UNK] datasets). The accuracy of the classifier on the training and independent confirmatory datasets was 85% and 73% respectively. Regional cortical surface area measures-including those from the right superior frontal, right superior temporal, and bilateral insular cortices strongly contributed to classifying CHR-PS+ from HC. CHR-PS- and CHR-UNK individuals were more likely to be classified as HC compared to CHR-PS+ (classification rate to HC: CHR-PS+, 30%; CHR-PS-, 73%; CHR-UNK, 80%). We used multisite sMRI to train a classifier to predict psychosis onset in CHR individuals, and it showed promise predicting CHR-PS+ in an independent sample. The results suggest that when considering adolescent brain development, baseline MRI scans for CHR individuals may be helpful to identify their prognosis. Future prospective studies are required about whether the classifier could be actually helpful in the clinical settings.
- Published
- 2024
4. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study.
- Author
-
Byrne, Jonah, Healy, Colm, Föcking, Melanie, Susai, Subash, Mongan, David, Wynne, Kieran, Kodosaki, Eleftheria, Heurich, Meike, de Haan, Lieuwe, Hickie, Ian, Smesny, Stefan, Thompson, Andrew, Markulev, Connie, Young, Alison, Schäfer, Miriam, Riecher-Rössler, Anita, Mossaheb, Nilufar, Berger, Gregor, Schlögelhofer, Monika, Nordentoft, Merete, Chen, Eric, Verma, Swapna, Nieman, Dorien, Woods, Scott, Cornblatt, Barbara, Stone, William, Addington, Jean, Walker, Elaine, Cannon, Tyrone, Cannon, Mary, McGorry, Pat, Amminger, Paul, Cagney, Gerard, Nelson, Barnaby, Jeffries, Clark, Perkins, Diana, Cotter, David, Mathalon, Daniel, Bearden, Carrie, and Cadenhead, Kristin
- Subjects
coagulation ,complement ,high risk ,immune ,model ,prediction ,proteome ,psychosis ,Humans ,Psychotic Disorders ,Female ,Male ,Biomarkers ,Proteomics ,Young Adult ,Adolescent ,Prodromal Symptoms ,Adult ,Disease Progression ,Longitudinal Studies ,Risk - Abstract
Psychosis risk prediction is one of the leading challenges in psychiatry. Previous investigations have suggested that plasma proteomic data may be useful in accurately predicting transition to psychosis in individuals at clinical high risk (CHR). We hypothesized that an a priori-specified proteomic prediction model would have strong predictive accuracy for psychosis risk and aimed to replicate longitudinal associations between plasma proteins and transition to psychosis. This study used plasma samples from participants in 3 CHR cohorts: the North American Prodrome Longitudinal Studies 2 and 3, and the NEURAPRO randomized control trial (total n = 754). Plasma proteomic data were quantified using mass spectrometry. The primary outcome was transition to psychosis over the study follow-up period. Logistic regression models were internally validated, and optimism-corrected performance metrics derived with a bootstrap procedure. In the overall sample of CHR participants (age: 18.5, SD: 3.9; 51.9% male), 20.4% (n = 154) developed psychosis within 4.4 years. The a priori-specified model showed poor risk-prediction accuracy for the development of psychosis (C-statistic: 0.51 [95% CI: 0.50, 0.59], calibration slope: 0.45). At a group level, Complement C8B, C4B, C5, and leucine-rich α-2 glycoprotein 1 (LRG1) were associated with transition to psychosis but did not surpass correction for multiple comparisons. This study did not confirm the findings from a previous proteomic prediction model of transition from CHR to psychosis. Certain complement proteins may be weakly associated with transition at a group level. Previous findings, derived from small samples, should be interpreted with caution.
- Published
- 2024
5. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.
- Author
-
Wannan, Cassandra, Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin, McGorry, Patrick, Mittal, Vijay, Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey, Perez, Jesus, Perkins, Diana, Powers, Albert, Roalf, David, Sabb, Fred, Schiffman, Jason, Shah, Jai, Smesny, Stefan, Spark, Jessica, Stone, William, Strauss, Gregory, Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge, Wolf, Daniel, Wolff, Phillip, Wood, Stephen, Yung, Alison, Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo, Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M, Cho, Youngsun, Cotter, David, DAlfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel, Gur, Ruben, Hamilton, Holly, Hoftman, Gil, Jacobs, Grace, Jarcho, Johanna, Ji, Jie, Kohler, Christian, Lalousis, Paris, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero, Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle, Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod, Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce, Walsh, Barbara, Whitford, Thomas, Wigman, Johanna, Yao, Beier, Yuen, Hok, Ahmed, Uzair, Byun, Andrew, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, and Langholm, Carsten
- Subjects
clinical high risk ,consortium ,early detection ,prediction ,prevention ,psychosis ,Humans ,Psychotic Disorders ,Schizophrenia ,Prospective Studies ,Adult ,Prodromal Symptoms ,Young Adult ,International Cooperation ,Adolescent ,Research Design ,Male ,Female - Abstract
This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.
- Published
- 2024
6. The diagnostic accuracy of screening for psychosis spectrum disorders in behavioral health clinics integrated into primary care
- Author
-
Savill, Mark, Loewy, Rachel L, Niendam, Tara A, Porteus, A Jonathan, Rosenthal, Adi, Gobrial, Sarah, Meyer, Monet, Bolden, Khalima A, Lesh, Tyler A, Ragland, J Daniel, and Carter, Cameron S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Schizophrenia ,Mental Illness ,Clinical Research ,Mental Health ,Prevention ,Behavioral and Social Science ,Health Services ,Brain Disorders ,Serious Mental Illness ,4.2 Evaluation of markers and technologies ,4.4 Population screening ,Mental health ,Good Health and Well Being ,Humans ,Psychotic Disorders ,Surveys and Questionnaires ,Sensitivity and Specificity ,Psychiatry ,Primary Health Care ,Prodromal Symptoms ,Clinical high risk ,Integrated behavioral health ,Assessment ,Prodromal questionnaire ,PQ -B ,PQ-B ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Clinical sciences - Abstract
Screening for psychosis spectrum disorders in primary care could improve early identification and reduce the duration of untreated psychosis. However, the accuracy of psychosis screening in this setting is unknown. To address this, we conducted a diagnostic accuracy study of screening for psychosis spectrum disorders in eight behavioral health services integrated into primary care clinics. Patients attending an integrated behavioral health appointment at their primary care clinic completed the Prodromal Questionnaire - Brief (PQ-B) immediately prior to their intake assessment. This was compared to a diagnostic phone interview based on the Structured Interview for Psychosis Risk Syndromes (SIPS). In total, 145 participants completed all study procedures, of which 100 screened positive and 45 negative at a provisional PQ-B threshold of ≥20. The PQ-B was moderately accurate at differentiating psychosis spectrum from no psychosis spectrum disorders; a PQ-B distress score of ≥27 had a sensitivity and specificity of 71.2 % and 57.0 % respectively. In total, 66 individuals (45.5 %) met criteria for a psychosis spectrum disorder and 24 (16.7 %) were diagnosed with full psychosis, indicating a high prevalence of psychosis in the sample. Overall, screening for psychosis spectrum disorders in an IBH primary care setting identified a relatively high number of individuals and may identify people that would otherwise be missed. The PQ-B performed slightly less well than in population-based screening in community mental health settings. However, the findings suggest this may represent an effective way to streamline the pathway between specialty early psychosis programs and primary care clinics for those in need.
- Published
- 2024
7. Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk (SCORES)
- Author
-
National Institute of Mental Health (NIMH)
- Published
- 2024
8. Self-Care for Dementia Caregivers (Care2)
- Author
-
National Institute on Aging (NIA) and Sarah T. Stahl, PhD, Associate Professor of Psychiatry and Clinical and Assistant Professor of Translational Science
- Published
- 2024
9. A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
- Published
- 2024
10. Seeing the Light: Early Intervention in People at Risk for Bipolar Disorder
- Author
-
Else Treffers, Principal investigator
- Published
- 2024
11. Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimers Disease Randomized Controlled Trial.
- Author
-
Raman, R, Hussen, K, Donohue, M, Ernstrom, K, Holdridge, K, Langford, O, Molina-Henry, D, Pierce, A, Sims, J, Smith, A, Yaari, R, Aisen, P, Sperling, R, and Grill, J
- Subjects
A4 study ,Alzheimer’s disease ,attrition ,clinical trial ,preclinical AD ,study discontinuation ,Humans ,Alzheimer Disease ,Male ,Female ,Aged ,Patient Dropouts ,COVID-19 ,Prodromal Symptoms ,Australia ,United States ,Canada ,Positron-Emission Tomography ,Aged ,80 and over - Abstract
BACKGROUND: Participant discontinuation from study treatment in a clinical trial can leave a trial underpowered, produce bias in statistical analysis, and limit interpretability of study results. Retaining participants in clinical trials for the full study duration is therefore as important as participant recruitment. OBJECTIVE: This analysis aims to identify associations of pre-randomization characteristics of participants with premature discontinuation during the blinded phase of the Anti-Amyloid treatment in Asymptomatic AD (A4) Study. DESIGN: All A4 trial randomized participants were classified as having prematurely discontinued study during the blinded period of the study for any reason (dropouts) or completed the blinded phase of the study on treatment (completers). SETTING: The trial was conducted across 67 study sites in the United States, Canada, Japan and Australia through the global COVID-19 pandemic. PARTICIPANTS: The sample consisted of all 1169 A4 trial randomized participants. MEASUREMENTS: Pre-randomization demographic, clinical, amyloid PET and genetic predictors of study discontinuation were evaluated using a univariate generalized linear mixed model (GLMM), with discontinuation status as the binary outcome, each predictor as a fixed effect, and site as a random effect to account for differences among study sites in the trial. Characteristics significant at p
- Published
- 2024
12. Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands (Slow-SPEED-NL)
- Author
-
Stichting ParkinsonNL, ZonMw: The Netherlands Organisation for Health Research and Development, Michael J. Fox Foundation for Parkinson's Research, PARKINSONS UK, Cure Parkinsons, Edmond J. Safra Foundation, Davis Phinney Foundation, Donders Centre for Cognitive Neuroimaging, Radboud University Nijmegen, Anne Wojcicki Foundation, Sleep Medicine Centre Kempenhaeghe, Sleep Medicine Centre SEIN, Queen Mary University of London, 23andMe, Inc., Parkinsons Progression Markers Initiative (PPMI), Massachusetts General Hospital, Harvard School of Public Health (HSPH), IJsfontein B.V., Netherlands, Hoffmann-La Roche, Erasmus Medical Center, University of Illinois at Chicago, University of Rochester, University of Bristol, University of Plymouth, University of Luebeck, McGill University, and University of Pittsburgh
- Published
- 2024
13. Study of the different sleep disturbances during the prodromal phase of depression and mania in bipolar disorders.
- Author
-
Basquin, Louise, Maruani, Julia, Leseur, Jeanne, Mauries, Sibylle, Bazin, Balthazar, Pineau, Guillaume, Henry, Chantal, Lejoyeux, Michel, and Geoffroy, Pierre A.
- Subjects
- *
PATIENTS' attitudes , *SLEEP interruptions , *BIPOLAR disorder , *CHRONOBIOLOGY disorders , *RESTLESS legs syndrome , *HYPOMANIA - Abstract
Background: One of the challenges in bipolar disorder (BD) lies in early detection of the illness and its recurrences, to improve prognosis. Sleep disturbances (SD) have been proposed as reliable predictive markers of conversion. While preliminary studies have explored the relationship between SD and the onset of mood episodes, the results remain heterogeneous and a few have specifically examined patients' perception of prodromal symptoms and their progression until the episode occurs. Identifying prodromes represents a crucial clinical challenge, as it enables early intervention, thereby reducing the severity of BD. Therefore, the objective of this study is to better characterize and evaluate the progressive nature of SD as prodromal symptoms of mood episodes, and patients' perception of it. Methods: Patients diagnosed with BD, either hospitalized or seeking treatment for a (hypo)manic or depressive episode benefited from standardized questionnaires, structured interviews, and self‐report questionnaires to evaluate SD prior to the current episode, as well as sociodemographic and clinical information. Results: Out of the 41 patients included, 59% spontaneously reported SD prior to the episode, appearing 90 days before depression and 35 days before mania (pre‐indexed/spontaneous reports: 51.22% insomnia complaints, 4.88% hypersomnolence complaints, 7.32% parasomnias, 2.44% sleep movements). After inquiry about specific SD, the percentage of patients reporting prodromal SD increased significantly to 83%, appearing 210 days before depression and 112.5 days before mania (post‐indexed reports: 75.61% presented with insomnia complaints appearing 150 days before depression and 20 days before mania, 46.34% had hypersomnolence complaints appearing 60 days before depression, 43.9% had parasomnias appearing 210 days before depression and 22.5 days before mania, 36.59% had sleep movements appearing 120 days before depression and 150 days before mania). Of note, bruxism appeared in 35% of patients before mania, and restless legs syndrome in 20% of patients before depression. Conclusion: This study highlights the very high prevalence of SD prior to a mood episode in patients with BD with differences between depressive and manic episodes. The more systematic screening of sleep alterations of the prodromal phase improved the recognition and characterization of different symptoms onset by patients. This underscores the need for precise questioning regarding sleep patterns in patients, to better identify the moment of transition toward a mood episode, referred to as "Chronos syndrome". The study emphasizes the importance of educating patients about the disorder and its sleep prodromal symptoms to facilitate early intervention and prevent recurrences. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. The experience sampling methodology in psychosis risk states: A systematic review.
- Author
-
Bogudzińska, Bogna, Jaworski, Arkadiusz, Zajdel, Aleksandra, Skrzypek, Katarzyna, and Misiak, Błażej
- Subjects
- *
EMOTION regulation , *SOCIAL skills , *SOCIAL dynamics , *PSYCHOSES , *SAMPLING methods - Abstract
The experience sampling method (ESM) is a structured diary technique, which is used to assess thoughts, mood and appraise subjective experiences in daily life. It has been recognized as a useful tool for understanding the characteristics, dynamics, and underlying mechanisms of prodromal symptoms of psychosis. The present systematic review aimed to provide a qualitative synthesis of findings provided by the ESM studies conducted in people with psychosis risk states. A systematic review of the MEDLINE, ERIC, Academic Search Ultimate, and Health Source: Nursing/Academic Edition databases, utilizing search terms related to the ESM and the risk of psychosis was conducted. Out of 1069 publication records identified, 77 studies met the inclusion criteria for the review. Data were synthesized around the following topics: 1) assessment of symptoms dynamics and social functioning; 2) assessment of the mechanisms contributing to the emergence of psychotic experiences and 3) assessment of stress sensitivity. The studies have shown that negative emotions are associated with subsequent development of paranoia. The tendency to draw hasty conclusions, aberrant salience, self-esteem, and emotion regulation were the most frequently reported mechanisms associated with the emergence of psychotic experiences. Studies using the ESM also provided evidence for the role of stress sensitivity, in the development of psychotic symptoms. The ESM has widely been applied to studies investigating psychosis risk states, using a variety of protocols. Findings from this systematic review might inform future studies and indicate potential targets for interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Neuropsychiatric symptoms as a prodromal factor in Alzheimer's type neurodegenerative disease: A scoping review.
- Author
-
Ferreira, Diego Alves, Macedo, Lorena Barbosa Cunha, and Foss, Maria Paula
- Subjects
- *
ALZHEIMER'S disease , *NEURODEGENERATION , *SYMPTOMS , *EXECUTIVE function , *NEUROPSYCHOLOGICAL tests , *BRAIN diseases - Abstract
Objective: Identifying neuropsychiatric symptoms (NPS) can aid in the early detection of Alzheimer's disease (AD); however, there is still a need for a greater consensus. This review aims to delineate the predominant NPS, compile a comprehensive list of the most commonly employed NPS assessment tools, and corroborate the principal findings regarding the link between NPS and neuropsychological assessment and neurobiological substrates. Methods: To conduct this scoping review, we followed the Preferred Reporting Items for Systematic Reviews guidelines and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). We searched for relevant articles published between 2017 and 2023 in MEDLINE, PsycINFO, PubMed, Web of Science, and Cochrane Library. Results: Of the 61 eligible articles, depression, anxiety, and apathy were the main NPSs. The Neuropsychiatric Inventory Questionnaire and Neuropsychiatric Inventory were the primary assessment tools used to evaluate NPS. Correlations between NPS severity and neurobiological markers were considered clinically significant. Furthermore, clinical procedures prioritized the use of global cognitive screening tools, assessments of executive functions, and functionality evaluations. Conclusion: Standardization of procedures is necessary because of the diversity of methods. The data show that NPS can predict the etiology, severity, form, and type of disease progression, serving as a precursor sign of AD. The results of the most common cognitive screening tools and NPS instruments provided an interesting overview of future clinical approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Externally validated deep learning model to identify prodromal Parkinsons disease from electrocardiogram.
- Author
-
Karabayir, Ibrahim, Gunturkun, Fatma, Butler, Liam, Kamaleswaran, Rishikesan, Davis, Robert, Colletta, Kalea, Chinthala, Lokesh, Jefferies, John, Bobay, Kathleen, Ross, G, Petrovitch, Helen, Masaki, Kamal, Akbilgic, Oguz, Tanner, Caroline, and Goldman, Samuel
- Subjects
Humans ,Artificial Intelligence ,Case-Control Studies ,Deep Learning ,Parkinson Disease ,Prodromal Symptoms ,Electrocardiography - Abstract
Little is known about electrocardiogram (ECG) markers of Parkinsons disease (PD) during the prodromal stage. The aim of the study was to build a generalizable ECG-based fully automatic artificial intelligence (AI) model to predict PD risk during the prodromal stage, up to 5 years before disease diagnosis. This case-control study included samples from Loyola University Chicago (LUC) and University of Tennessee-Methodist Le Bonheur Healthcare (MLH). Cases and controls were matched according to specific characteristics (date, age, sex and race). Clinical data were available from May, 2014 onward at LUC and from January, 2015 onward at MLH, while the ECG data were available as early as 1990 in both institutes. PD was denoted by at least two primary diagnostic codes (ICD9 332.0; ICD10 G20) at least 30 days apart. PD incidence date was defined as the earliest of first PD diagnostic code or PD-related medication prescription. ECGs obtained at least 6 months before PD incidence date were modeled to predict a subsequent diagnosis of PD within three time windows: 6 months-1 year, 6 months-3 years, and 6 months-5 years. We applied a novel deep neural network using standard 10-s 12-lead ECGs to predict PD risk at the prodromal phase. This model was compared to multiple feature engineering-based models. Subgroup analyses for sex, race and age were also performed. Our primary prediction model was a one-dimensional convolutional neural network (1D-CNN) that was built using 131 cases and 1058 controls from MLH, and externally validated on 29 cases and 165 controls from LUC. The model was trained on 90% of the MLH data, internally validated on the remaining 10% and externally validated on LUC data. The best performing model resulted in an external validation AUC of 0.67 when predicting future PD at any time between 6 months and 5 years after the ECG. Accuracy increased when restricted to ECGs obtained within 6 months to 3 years before PD diagnosis (AUC 0.69) and was highest when predicting future PD within 6 months to 1 year (AUC 0.74). The 1D-CNN model based on raw ECG data outperformed multiple models built using more standard ECG feature engineering approaches. These results demonstrate that a predictive model developed in one cohort using only raw 10-s ECGs can effectively classify individuals with prodromal PD in an independent cohort, particularly closer to disease diagnosis. Standard ECGs may help identify individuals with prodromal PD for cost-effective population-level early detection and inclusion in disease-modifying therapeutic trials.
- Published
- 2023
17. Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
- Author
-
National Institute of Mental Health (NIMH) and David J. Miklowitz, Ph.D., Principal Investigator
- Published
- 2023
18. A single-center study of clinical characteristics of 171 hospitalized children with systemic lupus erythematosus
- Author
-
ZHU Guohao, WANG Dahai, LIN Yi, ZHANG Ranran, WANG Ying, CHANG Hong
- Subjects
lupus erythematosus, systemic ,child ,prodromal symptoms ,antigens, nuclear ,sex factors ,Medicine - Abstract
Objective To investigate the clinical characteristics at childhood-onset systemic lupus erythematosus (cSLE) in our hospital over the past decade, and to analyze the relationship with sex and anti-extractable nuclear antigen (ENA) antibodies. Methods We included 171 children with cSLE admitted to our hospital from January 2012 to December 2021, collecting their data on age, sex, onset symptoms, and system involvement, as well as serum complements C3 and C4, immunoglobulin, and ENA antibodies. We analyzed the clinical features at disease onset, compared the above indicators between sexes, and determined the relationship between anti-ENA antibodies and organ/system involvement. Results The misdiagnosis rate before the definitive diagnosis of the children was 43.27%. The initial symptoms were mainly rashes and fever (28.31% each). Hematological involvement occurred in 73.68% of the children. The proportion of anemia was significantly higher in females than in males (χ2=3.863,P
- Published
- 2024
- Full Text
- View/download PDF
19. Symptoms and age of prodromal Alzheimer's disease in Down syndrome: a systematic review and meta-analysis.
- Author
-
Shimizu, Eri, Goto-Hirano, Keiko, Motoi, Yumiko, Arai, Masami, and Hattori, Nobutaka
- Subjects
- *
ALZHEIMER'S disease , *DOWN syndrome , *MILD cognitive impairment , *SLEEP interruptions , *FRONTOTEMPORAL dementia , *APOLIPOPROTEIN E4 , *BRAIN diseases - Abstract
The diagnostic criteria for adult-onset Alzheimer's disease (AD) in patients with Down syndrome (DS) have not been standardised. This study investigated the specific symptoms of AD in the prodromal stage of DS, the mean age at diagnosis at each stage of dementia, and the relationship between intellectual disability (ID) and dementia. PubMed, Web of Science, and Embase were searched for studies on DS, AD, early-stage disease, initial symptoms, and prodromal dementia registered between January 2012 and January 2022. We also performed a meta-analysis of the differences between the mean age at prodromal symptoms and AD diagnosis and the proportion of mild cognitive impairment in patients with mild and moderately abnormal ID. We selected 14 articles reporting the behavioural and psychological symptoms of dementia (BPSD) and memory- and language-related impairments as early symptoms of AD in patients with DS. The specific symptoms of BPSD were classified into five categories: irritability (agitation), apathy, abnormal behaviour, adaptive functioning, and sleep disturbance. The mean age at the diagnosis of prodromal symptoms and AD dementia was 52.7 and 56.2 years, respectively (mean difference, + 3.11 years; 95% CI 1.82–4.40) in the meta-analysis. The diagnosis of mild dementia tended to correlate with ID severity (odds ratio [OR], 1.38; 95% CI 0.87–2.18). The features of behaviour-variant frontotemporal dementia may be clinically confirmed in diagnosing early symptoms of DS-associated AD (DSAD). Moreover, age-appropriate cognitive assessment is important. Further studies are required to evaluate DSAD using a combination of biomarkers and ID-related data. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Prodromal questionnaire (PQ‐16) dimensionality among Colombian adolescent school students.
- Author
-
Campo‐Arias, Adalberto, Herazo, Edwin, and Caballero‐Domínguez, Carmen Cecilia
- Abstract
Aims Methods Results Conclusion The study aimed to determine the dimensionality of the Spanish version of the PQ‐16 among Colombian adolescent school students.A validation study was designed with the participation of 334 Colombian adolescent students aged between 13 and 17 (
M = 15.2,SD = 1.1); 171 (52.1%) were girls, and 163 (47.9%) were boys, 229 (68.6%) were ninth‐grade students and 105 (31.4%) were tenth‐grade students. Confirmatory factor analysis was performed, internal consistency was calculated with the Kuder‐Richardson and McDonald's omega tests, and correlation with suicide ideation was computed with the Kendall correlation (r).The confirmatory factor analysis showed that the PQ‐16 adequately fit a unidimensional structure: RMSEA = 0.05 (90%CI 0.04‐0.06), CFI = 0.91, TLI = 0.90, SRMR = 0.05, chi‐squared = 193.18 (df = 102,p < 0.001) and normalized chi‐squared = 1.89. This factor presented high internal consistency: Kuder‐Richardson test and McDonald's omega of 0.83. The correlation between the PQ‐16 and suicide ideation wasr = 0.45 (p < 0.001).The PQ‐16 is a one‐dimensional tool with high internal consistency and correlation with suicide ideation among schooled adolescents. Further research should explore the PQ‐16 performance against a structured clinical interview. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
21. Early Release - Isolated Ocular Mpox without Skin Lesions, United States - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC
- Author
-
Nguyen, Minh T, Mentreddy, Akshay, Schallhorn, Julie, Chan, Matilda, Aung, Su, Doernberg, Sarah B, Babik, Jennifer, Miles, Kevin, Yang, Katherine, Lydon, Emily, Minter, Daniel J, Gonzales, John, Shantha, Jessica, Doan, Thuy, and Seitzman, Gerami D
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Ophthalmology and Optometry ,Eye Disease and Disorders of Vision ,Infectious Diseases ,Sexually Transmitted Infections ,Emerging Infectious Diseases ,Infection ,Good Health and Well Being ,United States ,Humans ,Middle Aged ,Mpox (monkeypox) ,Face ,Polymerase Chain Reaction ,Prodromal Symptoms ,RNA ,Viral ,California ,eye infection ,monkeypox virus ,mpox ,orthoviruses ,viruses ,Medical Microbiology ,Public Health and Health Services ,Microbiology ,Clinical sciences ,Epidemiology ,Health services and systems - Abstract
We report a case of a 53-year-old HIV-negative patient in San Francisco, California, USA, with no classic mpox prodromal symptoms or skin lesions who experienced fulminant, vision-threatening scleritis, keratitis, and uveitis. Deep sequence analysis identified monkeypox virus RNA in the aqueous humor. We confirmed the virus on the cornea and sclera by PCR.
- Published
- 2023
22. Characterizing sustained social anxiety in individuals at clinical high risk for psychosis: trajectory, risk factors, and functional outcomes
- Author
-
Deng, Wisteria, Addington, Jean, Bearden, Carrie E, Cadenhead, Kristin S, Cornblatt, Barbara A, Mathalon, Daniel H, Perkins, Diana O, Seidman, Larry J, Tsuang, Ming T, Woods, Scott W, Walker, Elaine F, and Cannon, Tyrone D
- Subjects
Prevention ,Schizophrenia ,Serious Mental Illness ,Behavioral and Social Science ,Brain Disorders ,Mental Health ,Aetiology ,2.3 Psychological ,social and economic factors ,Mental health ,Good Health and Well Being ,Humans ,Longitudinal Studies ,Psychotic Disorders ,Risk Factors ,Prodromal Symptoms ,Anxiety ,Comorbidity ,covariant trajectories ,outcome studies ,polygenic risk ,stress exposure ,Neurosciences ,Public Health and Health Services ,Psychology ,Psychiatry - Abstract
BackgroundWhile comorbidity of clinical high-risk for psychosis (CHR-P) status and social anxiety is well-established, it remains unclear how social anxiety and positive symptoms covary over time in this population. The present study aimed to determine whether there are more than one covariant trajectory of social anxiety and positive symptoms in the North American Prodrome Longitudinal Study cohort (NAPLS 2) and, if so, to test whether the different trajectory subgroups differ in terms of genetic and environmental risk factors for psychotic disorders and general functional outcome.MethodsIn total, 764 CHR individuals were evaluated at baseline for social anxiety and psychosis risk symptom severity and followed up every 6 months for 2 years. Application of group-based multi-trajectory modeling discerned three subgroups based on the covariant trajectories of social anxiety and positive symptoms over 2 years.ResultsOne of the subgroups showed sustained social anxiety over time despite moderate recovery in positive symptoms, while the other two showed recovery of social anxiety below clinically significant thresholds, along with modest to moderate recovery in positive symptom severity. The trajectory group with sustained social anxiety had poorer long-term global functional outcomes than the other trajectory groups. In addition, compared with the other two trajectory groups, membership in the group with sustained social anxiety was predicted by higher levels of polygenic risk for schizophrenia and environmental stress exposures.ConclusionsTogether, these analyses indicate differential relevance of sustained v. remitting social anxiety symptoms in the CHR-P population, which in turn may carry implications for differential intervention strategies.
- Published
- 2023
23. Do the Components of Attenuated Positive Symptoms Truly Represent One Construct?
- Author
-
Schiffman, Jason, Ellman, Lauren, Mittal, Vijay, Pratt, Danielle, and Bridgwater, Miranda
- Subjects
clinical high risk for psychosis ,conviction ,distress ,duration ,factor analysis ,frequency ,functional impairment ,symptom dimensions ,Humans ,Retrospective Studies ,Prodromal Symptoms ,Psychotic Disorders ,Factor Analysis ,Statistical ,Psychiatric Status Rating Scales - Abstract
BACKGROUND AND HYPOTHESES: Psychosis-risk inventories, like the Structured Interview for Psychosis-Risk Syndromes (SIPS), utilize symptom components and coalesce the information into a single-severity rating. These components include frequency, duration, in-the-moment conviction, retrospective insight, distress, and effect on social/role functioning. While combining components distills a great deal of important information into one practical symptom rating, this approach may mask important details of the greater clinical picture. STUDY DESIGN: Individuals at clinical high risk for psychosis (n = 115) were assessed with the SIPS Score Separable Components (SSSC) scale, created to accompany the SIPS positive items by dividing each item into the 7 components identified above. The latent structure of the SSSC was identified with an exploratory factor analysis (EFA). The factors were followed up with validation analyses including hypothesized cognitive, functioning, and symptom measures. Finally, clinical utility analyses were conducted to understand relationships between psychosis risk and common comorbidities. STUDY RESULTS: EFA revealed that the SSSC had 3 interpretable factors with the appropriate fit (rmsr = 0.018, TLI = 0.921): Conviction (in-the-moment conviction, retrospective insight), Distress-Impairment (distress, social/role functioning), and Frequency/Duration (frequency, duration). Conviction was minimally valid, Distress-Impairment had excellent validity, and Frequency/Duration was not related to any of the candidate validators. Conviction significantly predicted elevated psychosis risk. Distress-Impairment was related to common comorbid symptoms. Notably, the factors associated more strongly with clinical features than the traditional SIPS scores. CONCLUSIONS: The SSSC offers a supplemental approach to single-severity ratings, providing useful clinical insight, mechanistic understanding, and the potential for better capturing heterogeneity in this population.
- Published
- 2023
24. Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis.
- Author
-
Hagler, Matthew, Ferrara, Maria, Yoviene Sykes, Laura, Li, Fangyong, Addington, Jean, Walker, Elaine, Powers, Albert, Allen, Adrienne, Srihari, Vinod, Woods, Scott, Cannon, Tyrone, Cornblatt, Barbara, Perkins, Diana, Seidman, Larry, Mathalon, Daniel, Bearden, Carrie, Cadenhead, Kristin, and Tsuang, Ming
- Subjects
Clinical high risk ,Conversion ,Early detection ,First episode ,Sampling bias ,Humans ,Psychotic Disorders ,Longitudinal Studies ,Protective Factors ,North America ,Prodromal Symptoms - Abstract
Over the past two decades, research and clinical resources on clinical high risk (CHR) for psychosis have both expanded, with goals to better understanding risk and protective factors on the course of illness and inform early intervention efforts. However, some studies have highlighted potential sampling bias among CHR research studies, raising questions about generalizability of findings and inequitable access to early detection and intervention. The current study sought to explore these questions by comparing 94 participants in a CHR longitudinal monitoring study across North America (NAPLS-2) who converted to syndromal psychosis over the course of the study (CHR-CV) to 171 participants who presented for treatment at a localized first-episode psychosis service (FES) after converting. CHR-CV participants were significantly more likely to be White and have a college-educated parent, while FES participants were more likely to be Black and first- or second-generation immigrants. On average, CHR-CV participants were younger at onset of attenuated positive symptoms, had a longer period of attenuated symptoms prior to conversion, and were more likely to be treated with antipsychotics prior to conversion compared to those in FES programs. After controlling for time since conversion, CHR-CV participants had higher global functioning and were less likely to have experienced recent psychiatric hospitalization. Findings suggest that CHR research and FES clinics may be sampling from different populations, although conclusions are limited by inconsistent sampling frames and methods. Integrated early detection that targets defined geographic catchments may deliver more epidemiologically representative samples to both CHR research and FES.
- Published
- 2023
25. Ethnoracial discrimination and the development of suspiciousness symptoms in individuals at clinical high-risk for psychosis.
- Author
-
Michaels, Timothy, Carrión, Ricardo, Addington, Jean, McGlashan, Thomas, Perkins, Diana, Seidman, Larry, Stone, William, Walker, Elaine, Woods, Scott, Cornblatt, Barbara, Cannon, Tyrone, Keshavan, Matcheri, Mathalon, Daniel, Bearden, Carrie, Cadenhead, Kristin, and Tsuang, Ming
- Subjects
Clinical high-risk ,Paranoia ,Perceived discrimination ,Psychosis ,Racism ,Suspiciousness ,Humans ,Longitudinal Studies ,Prodromal Symptoms ,Psychotic Disorders ,Ethnicity ,Latent Class Analysis - Abstract
BACKGROUND AND HYPOTHESIS: While individuals at clinical high-risk (CHR) for psychosis experience higher levels of discrimination than healthy controls, it is unclear how these experiences contribute to the etiology of attenuated positive symptoms. The present study examined the association of perceived discrimination with positive symptoms in a cohort from the North American Prodrome Longitudinal Study (NAPLS2). It predicted that CHR individuals will report higher levels of lifetime and past year perceived discrimination related to their race and ethnicity (ethnoracial discrimination) and that this form of discrimination will be significantly associated with baseline positive symptoms. STUDY DESIGN: Participants included 686 CHR and 252 healthy controls. The present study examined data from the perceived discrimination (PD) scale, the Brief Core Schema Scale, and the Scale for the Psychosis-Risk Symptoms. Structural equation modeling was employed to examine whether negative schema of self and others mediated the relation of past year ethnoracial PD to baseline suspiciousness symptoms. RESULTS: CHR individuals report higher levels of past year and lifetime PD compared to healthy controls. Lifetime ethnoracial PD was associated with suspiciousness and total positive symptoms. Negative schema of self and others scores partially mediated the relation of past year ethnoracial PD to suspiciousness, one of five positive symptom criteria for CHR. CONCLUSIONS: For CHR individuals, past year ethnoracial discrimination was associated with negative beliefs about themselves and others, which was associated with suspiciousness. These findings contribute to an emerging literature characterizing the mechanisms by which discrimination contributes to the positive symptoms characterizing the CHR syndrome.
- Published
- 2023
26. REtinal and VIsual Cortical Response in Early PSYchosis (REVIPSY)
- Author
-
BioSerenity and Institut National de la Santé Et de la Recherche Médicale, France
- Published
- 2023
27. Sex- and Age-Specific Deviations in Cerebellar Structure and Their Link With Symptom Dimensions and Clinical Outcome in Individuals at Clinical High Risk for Psychosis.
- Author
-
Woods, Scott, Cannon, Tyrone, Walker, Elaine, Sefik, Esra, Boamah, Michelle, Addington, Jean, Cornblatt, Barbara, Keshavan, Matcheri, Perkins, Diana, Stone, William, Mathalon, Daniel, Bearden, Carrie, Cadenhead, Kristin, and Tsuang, Ming
- Subjects
CHR ,North American Prodrome Longitudinal Study ,prodrome ,schizophrenia ,structural magnetic resonance imaging ,ultra-high risk ,Adolescent ,Adult ,Child ,Female ,Humans ,Male ,Young Adult ,Age Factors ,Longitudinal Studies ,Prodromal Symptoms ,Psychotic Disorders ,Risk Factors ,White Matter - Abstract
BACKGROUND: The clinical high-risk (CHR) period offers a temporal window into neurobiological deviations preceding psychosis onset, but little attention has been given to regions outside the cerebrum in large-scale studies of CHR. Recently, the North American Prodrome Longitudinal Study (NAPLS)-2 revealed altered functional connectivity of the cerebello-thalamo-cortical circuitry among individuals at CHR; however, cerebellar morphology remains underinvestigated in this at-risk population, despite growing evidence of its involvement in psychosis. STUDY DESIGN: In this multisite study, we analyzed T1-weighted magnetic resonance imaging scans obtained from N = 469 CHR individuals (61% male, ages = 12-36 years) and N = 212 healthy controls (52% male, ages = 12-34 years) from NAPLS-2, with a focus on cerebellar cortex and white matter volumes separately. Symptoms were rated by the Structured Interview for Psychosis-Risk Syndromes (SIPS). The outcome by two-year follow-up was categorized as in-remission, symptomatic, prodromal-progression, or psychotic. General linear models were used for case-control comparisons and tests for volumetric associations with baseline SIPS ratings and clinical outcomes. STUDY RESULTS: Cerebellar cortex and white matter volumes differed between the CHR and healthy control groups at baseline, with sex moderating the difference in cortical volumes, and both sex and age moderating the difference in white matter volumes. Baseline ratings for major psychosis-risk dimensions as well as a clinical outcome at follow-up had tissue-specific associations with cerebellar volumes. CONCLUSIONS: These findings point to clinically relevant deviations in cerebellar cortex and white matter structures among CHR individuals and highlight the importance of considering the complex interplay between sex and age when studying the neuromaturational substrates of psychosis risk.
- Published
- 2023
28. Family communication and the efficacy of family focused therapy in individuals at clinical high risk for psychosis with comorbid anxiety
- Author
-
Cannon, Arianna C O'Brien, Caporino, Nicole E, O'Brien, Mary P, Miklowitz, David J, Addington, Jean M, and Cannon, Tyrone D
- Subjects
Clinical and Health Psychology ,Psychology ,Mental Health ,Clinical Trials and Supportive Activities ,Prevention ,Serious Mental Illness ,Behavioral and Social Science ,Brain Disorders ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.6 Psychological and behavioural ,Mental health ,Humans ,Anxiety ,Anxiety Disorders ,Communication ,Longitudinal Studies ,Prodromal Symptoms ,Psychotic Disorders ,anxiety ,clinical high risk for psychosis ,enhanced care ,family focused treatment ,family problem-solving interaction task ,Clinical Sciences ,Psychiatry ,Clinical sciences ,Neurosciences ,Clinical and health psychology - Abstract
AimComorbid anxiety disorder is related to greater illness severity among individuals at clinical high risk (CHR) for psychosis, but its potential role in moderating response to Family Focused Therapy (FFT) for CHR is unexamined. We investigated whether comorbid anxiety disorder in CHR individuals is associated with less constructive communication during family problem-solving interactions, whether their communication skills differentially improve after FFT, and whether FFT is effective in reducing anxiety in this population.MethodsIndividuals recruited into the second phase of the 8-site North American Prodrome Longitudinal Study (NAPLS2) participated (N = 129). They were randomly assigned to 18-sessions of FFT-CHR or three-sessions of Enhanced Care (EC). Participants completed a diagnostic interview at pre-treatment, a family interaction task at pre-treatment and 6-months, and a self-report anxiety measure at pretreatment, 6 and 12-months.ResultsIndividuals at CHR with comorbid anxiety engaged in more negative and fewer positive behaviours during family problem-solving interactions at pre-treatment than did those without comorbid anxiety. There was a significant interaction between anxiety diagnosis and time on interactional behaviour scores, such that individuals at CHR with an anxiety diagnosis showed a greater decrease in negative behaviours and increase in positive behaviours from baseline to 6-months than those without anxiety disorder(s) regardless of treatment condition. However, individuals' self-reported anxiety symptoms decreased more in FFT-CHR than in EC from pre-treatment to 12-month follow-up, regardless of anxiety diagnoses.ConclusionsIndividuals at CHR with symptoms of anxiety benefit from family interventions in showing reductions in anxiety and improvements in family communication.
- Published
- 2023
29. Accelerated cortical thinning precedes and predicts conversion to psychosis: The NAPLS3 longitudinal study of youth at clinical high-risk
- Author
-
Collins, Meghan A, Ji, Jie Lisa, Chung, Yoonho, Lympus, Cole A, Afriyie-Agyemang, Yvette, Addington, Jean M, Goodyear, Bradley G, Bearden, Carrie E, Cadenhead, Kristin S, Mirzakhanian, Heline, Tsuang, Ming T, Cornblatt, Barbara A, Carrión, Ricardo E, Keshavan, Matcheri, Stone, Wiliam S, Mathalon, Daniel H, Perkins, Diana O, Walker, Elaine F, Woods, Scott W, Powers, Albert R, Anticevic, Alan, and Cannon, Tyrone D
- Subjects
Behavioral and Social Science ,Prevention ,Serious Mental Illness ,Pediatric ,Mental Health ,Neurosciences ,Brain Disorders ,Clinical Research ,Humans ,Female ,Adolescent ,Male ,Longitudinal Studies ,Cerebral Cortical Thinning ,Ethnicity ,Minority Groups ,Psychotic Disorders ,Prodromal Symptoms ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Psychiatry - Abstract
Progressive grey matter loss has been demonstrated among clinical high-risk (CHR) individuals who convert to psychosis, but it is unknown whether these changes occur prior to psychosis onset. Identifying illness-related neurobiological mechanisms that occur prior to conversion is essential for targeted early intervention. Among participants in the third wave of the North American Prodrome Longitudinal Study (NAPLS3), this report investigated if steeper cortical thinning was observable prior to psychosis onset among CHR individuals who ultimately converted (CHR-C) and assessed the shortest possible time interval in which rates of cortical thinning differ between CHR-C, CHR non-converters (CHR-NC), and health controls (HC). 338 CHR-NC, 42 CHR-C, and 62 HC participants (age 19.3±4.2, 44.8% female, 52.5% racial/ethnic minority) completed up to 5 MRI scans across 8 months. Accelerated thinning among CHR-C compared to CHR-NC and HC was observed in multiple prefrontal, temporal, and parietal cortical regions. CHR-NC also exhibited accelerated cortical thinning compared to HC in several of these areas. Greater percent decrease in cortical thickness was observed among CHR-C compared to other groups across 2.9±1.8 months, on average, in several cortical areas. ROC analyses discriminating CHR-C from CHR-NC by percent thickness change in a left hemisphere region of interest, scanner, age, age2, and sex had an AUC of 0.74, with model predictive power driven primarily by percent thickness change. Findings indicate that accelerated cortical thinning precedes psychosis onset and differentiates CHR-C from CHR-NC and HC across short time intervals. Mechanisms underlying cortical thinning may provide novel treatment targets prior to psychosis onset.
- Published
- 2023
30. Proposal for a Biologic Staging System of Parkinson’s Disease
- Author
-
Chahine, Lana M, Merchant, Kalpana, Siderowf, Andrew, Sherer, Todd, Tanner, Caroline, Marek, Kenneth, and Simuni, Tanya
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Parkinson's Disease ,Neurodegenerative ,Brain Disorders ,Clinical Research ,Aging ,Neurological ,Humans ,Parkinson Disease ,alpha-Synuclein ,Lewy Body Disease ,Lewy Bodies ,Nerve Degeneration ,Biomarkers ,Prodromal Symptoms ,Biological Products ,Parkinson’s disease ,alpha-synuclein ,biomarkers ,disease staging ,Biochemistry and Cell Biology - Abstract
The Parkinson's disease (PD) research field has seen the advent of several promising biomarkers and a deeper understanding of the clinical features of the disease from the earliest stages of pathology to manifest disease. Despite progress, a biologically based PD staging system does not exist. Such staging would be a useful framework within which to model the disease, develop and validate biomarkers, guide therapeutic development, and inform clinical trials design. We propose that the presence of aggregated neuronal α-synuclein, dopaminergic neuron dysfunction/degeneration, and clinical signs and symptoms identifies a group of individuals that have Lewy body pathology, which in early stages manifests with what is now referred to as prodromal non-motor features and later stages with the manifestations of PD and related Lewy body diseases as defined by clinical diagnostic criteria. Based on the state of the field, we herein propose a definition and staging of PD based on biology. We present the biologic basis for such a staging system and review key assumptions and evidence that support the proposed approach. We identify gaps in knowledge and delineate crucial research priorities that will inform the ultimate integrated biologic staging system for PD.
- Published
- 2023
31. Longitudinal impact of trauma in the North American Prodrome Longitudinal Study-3.
- Author
-
Farris, Megan, Braun, Amy, Liu, Lu, Cornblatt, Barbara, Keshavan, Matcheri, McGlashan, Thomas, Perkins, Diana, Stone, William, Walker, Elaine, Woods, Scott, Cannon, Tyrone, Addington, Jean, Mathalon, Daniel, Bearden, Carrie, Cadenhead, Kristin, and Tsuang, Ming
- Subjects
clinical high risk ,clinical outcomes ,depression ,transition to psychosis ,trauma ,Humans ,Prodromal Symptoms ,Longitudinal Studies ,Psychotic Disorders ,North America - Abstract
AIM: Individuals at clinical high risk (CHR) for psychosis have been shown to experience more trauma than the general population. However, although the effects of trauma appear to impact some symptoms it does not seem to increase the risk of transition to psychosis. The aim of this article was to examine the prevalence of trauma, and its association with longitudinal clinical and functional outcomes in a large sample of CHR individuals. METHODS: From the North American Prodrome Longitudinal Study-3 (NAPLS-3) 690 CHR individuals and 91 healthy controls from nine study sites between 2015 and 2018 were assessed. Historical trauma experiences were captured at baseline. Participants completed longitudinal assessments measuring clinical outcomes including positive and negative symptoms, depression, social and role functioning and assessing transition to psychosis. RESULTS: From the 690 CHR participants and 96 healthy controls, 343 (49.6%) and 15 (15.6%), respectively, reported a history of trauma (p
- Published
- 2022
32. Prodromal symptoms and the duration of untreated psychosis in first episode of psychosis patients: what differences are there between early vs. adult onset and between schizophrenia vs. bipolar disorder?
- Author
-
Baeza, Inmaculada, de la Serna, Elena, Mezquida, Gisela, Cuesta, Manuel J., Vieta, Eduard, Amoretti, Silvia, Lobo, Antonio, González-Pinto, Ana, Díaz-Caneja, Covadonga M., Corripio, Iluminada, Valli, Isabel, Puig, Olga, Mané, Anna, Bioque, Miquel, Ayora, Miriam, Bernardo, Miquel, Castro-Fornieles, Josefina, the PEPs group, García-Rizo, Clemente, and González-Díaz, Jairo
- Subjects
- *
DIAGNOSIS of bipolar disorder , *DIAGNOSIS of schizophrenia , *RESEARCH , *PSYCHOSES , *RESEARCH methodology , *INTERVIEWING , *COMPARATIVE studies , *DISEASE duration , *AGE factors in disease , *DESCRIPTIVE statistics , *LONGITUDINAL method - Abstract
To assess the role of age (early onset psychosis-EOP < 18 years vs. adult onset psychosis-AOP) and diagnosis (schizophrenia spectrum disorders-SSD vs. bipolar disorders-BD) on the duration of untreated psychosis (DUP) and prodromal symptoms in a sample of patients with a first episode of psychosis. 331 patients with a first episode of psychosis (7–35 years old) were recruited and 174 (52.6%) diagnosed with SSD or BD at one-year follow-up through a multicenter longitudinal study. The Symptom Onset in Schizophrenia (SOS) inventory, the Positive and Negative Syndrome Scale and the structured clinical interviews for DSM-IV diagnoses were administered. Generalized linear models compared the main effects and group interaction. 273 AOP (25.2 ± 5.1 years; 66.5% male) and 58 EOP patients (15.5 ± 1.8 years; 70.7% male) were included. EOP patients had significantly more prodromal symptoms with a higher frequency of trouble with thinking, avolition and hallucinations than AOP patients, and significantly different median DUP (91 [33–177] vs. 58 [21–140] days; Z = − 2.006, p = 0.045). This was also significantly longer in SSD vs. BD patients (90 [31–155] vs. 30 [7–66] days; Z = − 2.916, p = 0.004) who, moreover had different profiles of prodromal symptoms. When assessing the interaction between age at onset (EOP/AOP) and type of diagnosis (SSD/BD), avolition was significantly higher (Wald statistic = 3.945; p = 0.047), in AOP patients with SSD compared to AOP BD patients (p = 0.004). Awareness of differences in length of DUP and prodromal symptoms in EOP vs. AOP and SSD vs. BD patients could help improve the early detection of psychosis among minors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Identifying prior signals of bipolar disorder using primary care electronic health records: a nested case–control study.
- Author
-
Morgan, Catharine, Ashcroft, Darren M, Chew-Graham, Carolyn A, Sperrin, Matthew, Webb, Roger T, Francis, Anya, Scott, Jan, and Yung, Alison R
- Subjects
ELECTRONIC health records ,BIPOLAR disorder ,PRIMARY health care ,SLEEP interruptions ,CASE-control method - Abstract
Background: Bipolar disorders are serious mental illnesses, yet evidence suggests that the diagnosis and treatment of bipolar disorder can be delayed by around 6 years. Aim: To identify signals of undiagnosed bipolar disorder using routinely collected electronic health records. Design and setting: A nested case–control study conducted using the UK Clinical Practice Research Datalink (CPRD) GOLD dataset, an anonymised electronic primary care patient database linked with hospital records. 'Cases' were adult patients with incident bipolar disorder diagnoses between 1 January 2010 and 31 July 2017. Method: The patients with bipolar disorder (the bipolar disorder group) were matched by age, sex, and registered general practice to 20 'controls' without recorded bipolar disorder (the control group). Annual episode incidence rates were estimated and odds ratios from conditional logistic regression models were reported for recorded health events before the index (diagnosis) date. Results: There were 2366 patients with incident bipolar disorder diagnoses and 47 138 matched control patients (median age 40 years and 60.4% female: n = 1430/2366 with bipolar disorder and n = 28 471/47 138 without). Compared with the control group, the bipolar disorder group had a higher incidence of diagnosed depressive, psychotic, anxiety, and personality disorders and escalating self-harm up to 10 years before a bipolar disorder diagnosis. Sleep disturbance, substance misuse, and mood swings were more frequent among the bipolar disorder group than the control group. The bipolar disorder group had more frequent face-to-face consultations, and were more likely to miss multiple scheduled appointments and to be prescribed ≥3 different psychotropic medication classes in a given year. Conclusion: Psychiatric diagnoses, psychotropic prescriptions, and health service use patterns might be signals of unreported bipolar disorder. Recognising these signals could prompt further investigation for undiagnosed significant psychopathology, leading to timely referral, assessment, and initiation of appropriate treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Adapting the early recognition inventory ERIraos to Estonian: A validation study.
- Author
-
Sirts, Kairit, Anni, Kätlin, Balõtšev, Roman, Jakobsoo, Siim, Jaanson, Kirti‐Ly, and Haring, Liina
- Abstract
Aim Methods Results Conclusions Validated assessment tools are needed to identify clinically high risk for psychosis. This study aimed to validate the early recognition inventory ERIraos, which consists of the ERIraos Checklist for risk screening and the ERIraos Symptom List for a more thorough risk assessment in the Estonian language to detect psychotic prodromal symptoms.A prospective cohort study provided an opportunity to evaluate the characteristics of the ERIraos instrument in predicting the increased risk of a psychotic disorder in the future. The 177 study participants, aged 13–42 years old, were divided into groups without an increased risk and three risk groups with different risk severity levels based on the ERIraos Symptom List assessment.The results indicated excellent inter‐rater reliability for the ERIraos Symptom List total score. The ability of the ERIraos checklist to screen persons with an elevated psychosis risk was very good (ROC‐AUC = 0.86). The capability of the ERIraos Symptom List scores to predict the probability of transitioning to psychosis within 2 years was very good (ROC‐AUC = 0.83). Brief limited intermittent psychotic symptoms and observable behavioural and affective symptoms were statistically significant predictors of transition to psychosis. There were strong and statistically significant correlations between the ERIraos Symptom List scores and other clinical measures assessing functioning and psychopathology.The results of this study demonstrate the reliability and validity of the Estonian version of the ERIraos instrument and support the usability of ERIraos as a two‐step tool for the early recognition of psychosis risk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. The Italian version of the 16‐item Prodromal Questionnaire (PQ‐16) and its psychometric features in help‐seeking ultra‐high‐risk subjects and in the general population.
- Author
-
Parabiaghi, Alberto, Rossi, Alessandro Alberto, Castelnovo, Anna, Fabro, Lorenzo, Mannarini, Stefania, and Percudani, Mauro Emilio
- Abstract
Background Methods Results Conclusions Increasing attention to the early stages of psychosis and the identification of symptomatic prodromal states have led to the development of a growing number of screening tools. The 16‐item version of the Prodromal Questionnaire (PQ‐16) is a worldwide used self‐administered tool for this purpose. However, to date, fundamental psychometric properties of PQ‐16 were not thoroughly investigated. This study aimed to examine the structural validity, measurement invariance, reliability and other psychometrical properties of the Italian version of the PQ‐16 (iPQ‐16) in help‐seeking individuals and in the general population.The iPQ‐16 was administered to 449 young outpatients attending six community mental health services and to 318 control participants enrolled in educational environment. Confirmatory factor analyses (CFAs), measurement invariance (MI) between the help‐seeking group and the general population sample, convergent validity, test–retest reliability, internal consistency, and prevalence analyses were performed. Lastly, the validity of the adopted PQ‐16 cut‐offs through Receiver Operating Characteristic (ROC) curves plotted against CAARMS diagnoses was also tested.CFAs confirmed the single‐factor structure for the iPQ‐16 and scalar MI was reached. The iPQ‐16 showed high internal consistency, test–retest reliability, convergent validity, and acceptable diagnostic accuracy. ROC analysis suggested a score of ≥4 as best cut‐off.The iPQ‐16 represents a valid and reliable questionnaire for the assessment of high mental risk in both Italian outpatients and general student population. It has good psychometric properties and is easy to implement as UHR screening for clinical as well as research purposes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Intensity of Psychoactive Substance Use Affects the Occurrence of Prodromal Symptoms of Psychosis.
- Author
-
Więckiewicz, Gniewko, Florczyk, Iga, Stokłosa, Maciej, Jurga, Marta, Gorczyca, Piotr, and Kotlicka-Antczak, Magdalena
- Subjects
- *
SUBSTANCE abuse , *SUBSTANCE-induced disorders , *PSYCHOSES , *SYMPTOMS - Abstract
Background: Psychosis is defined as a series of symptoms that impair the mind and lead to a kind of loss of reference to reality. Development of psychosis is usually preceded by the appearance of prodromal symptoms. Numerous attempts have been made to find out how psychoactive substances can influence the onset and development of psychotic disorders, but to date there are no studies that show a link between the onset of prodromal symptoms and the use of psychoactive substances. Methods: A survey consisting of epidemiological and demographic questions, the Drug Use Disorders Identification Test (DUDIT), and the Prodromal Questionnaire Brief Version (PQ-B) was conducted on social media among users of illegal psychoactive substances, covering 703 study participants. Results: A total of 39.8% of the respondents had been treated by a psychiatrist, and the most popular drugs used by respondents in their lifetime were tetrahydrocannabinol-containing products, MDMA, amphetamines, and LSD. A significant correlation was found between the DUDIT and the PQ-B values. Conclusions: Intensity of psychoactive substance use correlated positively with the risk of appearance and intensity of prodromal symptoms of psychosis. Early exposure to psychoactive substances increased the risk of heavy substance use in adulthood and led to more frequent prodromal states. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease.
- Author
-
Casciano, Fabio, Zauli, Enrico, Celeghini, Claudio, Caruso, Lorenzo, Gonelli, Arianna, Zauli, Giorgio, and Pignatelli, Angela
- Subjects
- *
NEURODEGENERATION , *DOPAMINERGIC neurons , *ALZHEIMER'S disease , *FUNCTIONAL magnetic resonance imaging , *PARKINSON'S disease , *DIAGNOSIS - Abstract
Neurodegenerative diseases are an increasingly common group of diseases that occur late in life with a significant impact on personal, family, and economic life. Among these, Alzheimer's disease (AD) and Parkinson's disease (PD) are the major disorders that lead to mild to severe cognitive and physical impairment and dementia. Interestingly, those diseases may show onset of prodromal symptoms early after middle age. Commonly, the evaluation of these neurodegenerative diseases is based on the detection of biomarkers, where functional and structural magnetic resonance imaging (MRI) have shown a central role in revealing early or prodromal phases, although it can be expensive, time-consuming, and not always available. The aforementioned diseases have a common impact on the visual system due to the pathophysiological mechanisms shared between the eye and the brain. In Parkinson's disease, α-synuclein deposition in the retinal cells, as well as in dopaminergic neurons of the substantia nigra, alters the visual cortex and retinal function, resulting in modifications to the visual field. Similarly, the visual cortex is modified by the neurofibrillary tangles and neuritic amyloid β plaques typically seen in the Alzheimer's disease brain, and this may reflect the accumulation of these biomarkers in the retina during the early stages of the disease, as seen in postmortem retinas of AD patients. In this light, the ophthalmic evaluation of retinal neurodegeneration could become a cost-effective method for the early diagnosis of those diseases, overcoming the limitations of functional and structural imaging of the deep brain. This analysis is commonly used in ophthalmic practice, and interest in it has risen in recent years. This review will discuss the relationship between Alzheimer's disease and Parkinson's disease with retinal degeneration, highlighting how retinal analysis may represent a noninvasive and straightforward method for the early diagnosis of these neurodegenerative diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine.
- Author
-
Dermitzakis, Emmanouil V., Vikelis, Michail, Xiromerisiou, Georgia, Rallis, Dimitrios, Soldatos, Panagiotis, Litsardopoulos, Pantelis, Rikos, Dimitrios, and Argyriou, Andreas A.
- Subjects
- *
MIGRAINE , *SYMPTOMS , *ALLERGIES , *PREVENTIVE medicine , *NAUSEA , *CLUSTER headache - Abstract
Objective: To investigate whether the incidence of triggers, prodromal symptoms, hypersensitivity symptoms accompanying headache and responses to triptans were modified during a continuous 9-month fremanezumab therapy for migraine prophylaxis. Patients and methods: We studied 63 patients with high-frequency episodic migraine (HFEM). Enrolled patients received fremanezumab for nine consecutive months before defining the response rates and being stratified into treatment responders (≥50–74% reduction in monthly headache days (MHDs)), super responders (≥75%), partial non-responders (<50%) and super non-responders (<30%). Through headache diaries, patients provided data in order to document the impact of fremanezumab on the incidence of triggers, associated symptoms followed by headache and response to triptans (the use of the migraine treatment optimization questionnaire-4 (mTOQ-4)) during the 9-month treatment period. Results: Fremanezumab had early (after 3 monthly cycles) beneficial effects on the response to triptans in the majority of responders with relevant increases in mTOQ-4 scoring, but also in half of partial non-responders. A significant reduction in median days with migraine-associated symptoms was seen in responders after 6 months of therapy with fremanezumab, mostly for osmophobia, photophobia, phonophobia and nausea/vomiting, but partial non-responders also benefited. Likewise, the incidence of self-reported prodromal symptoms was significantly reduced in responders and was modestly diminished in partial non-responders. Triggers remained unaffected in both responders and non-responders. Conclusions: Fremanezumab given for at least 6–9 months may exert neuromodulatory effects in the migraine brain. These effects could result both in the inhibition of migraine chronification, but also in the diminishing of the magnitude of migraine-associated symptoms, mostly in responders and in partial non-responders. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Modelling the effects of the exposome score within the extended psychosis phenotype.
- Author
-
Rejek, Maksymilian and Misiak, Błażej
- Subjects
- *
ENVIRONMENTAL exposure , *PSYCHOSES , *PARANOIA , *PSYCHIATRIC treatment , *ADVERSE childhood experiences , *PHENOTYPES - Abstract
It has been reported that cumulative measures of risk factors for psychosis might help to predict its development. However, it remains unknown as to whether these measures are also associated with the extended psychosis phenotype that refers to a continuum of features bridging subclinical symptoms with clinically relevant outcomes. In this study, we aimed to investigate the association of the exposome score (ES) with psychosis risk in a non-clinical population. A total of 1100 non-clinical adults (aged 18–35 years, 51.4% females) with a negative history of psychiatric treatment were recruited. The Prodromal Questionnaire–16 (PQ–16) was used to screen for psychosis risk. Self-reports were used to record environmental exposures. The ES was significantly higher in participants with the positive PQ-16 screening. Specifically, the prevalence of obstetric complications, non–right handedness, all categories of childhood trauma, and problematic cannabis use was significantly higher in this group of participants. A network analysis demonstrated that the ES was directly connected not only to items representing psychotic experiences ("paranoid thoughts", "a lack of control over own ideas or thoughts", "thought echo", and "being distracted by distant sounds") but also those covering depressive or anxiety symptoms ("uninterested in things used to enjoy" and "feeling anxious when meeting people for the first time"). In conclusion, the ES is associated with the extended psychosis phenotype, suggesting its potential to identify individuals who may benefit from further psychosis risk assessment. The ES appears to contribute to non-specific psychopathology, which may, in some cases, progress to psychosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Point de vue neuroconstructiviste : modèle développemental du trouble du spectre de l'autisme.
- Author
-
Plusquellec, A. and Vandromme, L.
- Subjects
- *
AUTISM spectrum disorders , *PSYCHOLOGY , *NEURODEVELOPMENTAL treatment , *SCIENTIFIC literature , *PHILOSOPHY - Abstract
Comprendre comment le trouble du spectre de l'autisme apparaît chez l'enfant est un enjeu essentiel de la recherche actuelle. En effet, cela ouvre la possibilité à un dépistage plus précoce de ce trouble neurodéveloppemental afin de faciliter l'accès aux soins pour ces enfants. Dans ce but, nous proposons ici un modèle développemental du trouble du spectre de l'autisme basé sur trois phases successives : une première phase d'indifférenciation, de la naissance jusqu'à 6 mois ; une phase prodromique de 6 à 12 mois et une phase symptomatique à partir de 12 mois. La description de ces phases s'appuie sur une revue de littérature scientifique récente. Understanding how autism spectrum disorder occurs in children is a key issue in current research. This opens up the possibility of earlier detection of this neurodevelopmental disorder in order to facilitate access to care for these children. To this end, we propose here a developmental model of autism spectrum disorder based on three successive phases: a first undifferentiated phase, from birth to 6 months; a prodromal phase from 6 to 12 months; and a symptomatic phase from 12 months. The description of these phases is based on a recent scientific literature review. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Elevated emotion reactivity and emotion regulation in individuals at clinical high risk for developing psychosis and those diagnosed with a psychotic disorder.
- Author
-
Bachman, Peter, Hayes, Rebecca, Catalano, Sabrina, Jalbrzikowski, Maria, Vines, Leah, and Bridgwater, Miranda
- Subjects
affective ,negative symptoms ,prodromal ,schizophrenia-spectrum ,social functioning ,Adolescent ,Cross-Sectional Studies ,Emotional Regulation ,Emotions ,Humans ,Prodromal Symptoms ,Psychotic Disorders - Abstract
AIMS: Disrupted affective processes are core features of psychosis; yet emotion reactivity and emotion regulation impairments have not been fully characterized in individuals at clinical high-risk for developing psychosis (CHR) or adolescents diagnosed with a psychotic disorder (AOP). Characterizing these impairments may provide a fuller understanding of factors contributing to psychosis risk and psychosis onset. Using cross-sectional and longitudinal data, we evaluated (1) group-level effects of emotion reactivity and regulation, (2) stability of group-level effects over time and age, (3) relationships between emotion reactivity and regulation, and (4) associations between these measures and psychosocial functioning and clinical symptomatology. METHODS: Eighty-seven participants (CHR = 32, TD = 42, AOP = 13; 12-25 years, 1-5 visits) completed the Emotion Reactivity Scale, Difficulties in Emotion Regulation Scale, and Emotion Regulation Questionnaire. We assessed psychotic symptoms with the Structured Interview for Prodromal Syndromes and measured real-world functioning with the Global Functioning: Social and Role Scales. We used analysis of variance to assess Aim 1 and linear mixed models to address Aims 2-4. RESULTS: CHR and AOP endorsed experiencing heightened levels of emotion reactivity and greater difficulty utilizing emotion regulation strategies compared to TD. These impairments were stable across time and adolescent development. Greater levels of emotion reactivity were associated with greater emotion regulation impairments. Greater impairments in emotion regulation were associated with lower social functioning and greater negative symptom severity. CONCLUSION: Therapeutic interventions designed to reduce emotion reactivity and improve ones ability to utilize emotion regulation strategies may be effective in reducing clinical symptomatology and improving real-world functioning in CHR and AOP.
- Published
- 2022
42. Family-focused therapy for individuals at high clinical risk for psychosis: A confirmatory efficacy trial.
- Author
-
Miklowitz, David J, Addington, Jean M, O'Brien, Mary P, Denenny, Danielle M, Weintraub, Marc J, Zinberg, Jamie L, Mathalon, Daniel H, Cornblatt, Barbara A, Friedman-Yakoobian, Michelle S, Stone, William S, Cadenhead, Kristin S, Woods, Scott W, Sugar, Catherine A, Cannon, Tyrone D, and Bearden, Carrie E
- Subjects
Humans ,Communication ,Social Adjustment ,Psychotic Disorders ,Family Therapy ,Adolescent ,Adult ,Young Adult ,expressed emotion ,family therapy ,prodromal symptoms ,psychotic disorders ,social adjustment ,Clinical Research ,Serious Mental Illness ,Mental Health ,Pediatric ,Prevention ,Clinical Trials and Supportive Activities ,Comparative Effectiveness Research ,Behavioral and Social Science ,6.6 Psychological and behavioural ,Evaluation of treatments and therapeutic interventions ,Mental health ,Good Health and Well Being ,Clinical Sciences ,Psychology ,Psychiatry - Abstract
AimsYoung people with attenuated psychotic symptoms (APS), brief intermittent psychosis, and/or genetic risk and functional deterioration are at high risk for developing psychotic disorders. In a prior trial, family-focused therapy for clinical high risk youth (FFT-CHR) was more effective than brief psychoeducation in reducing APS severity over 6 months. This 7-site trial will compare the efficacy of FFT-CHR to a psychoeducational and supportive intervention (enhanced care) on APS and social functioning in CHR individuals over 18 months.MethodsParticipants (N = 220, ages 13-25 years) with a CHR syndrome will be randomly assigned to FFT-CHR (18 1-h sessions of family psychoeducation and communication/problem-solving skills training) or enhanced care (3 1-h family psychoeducational sessions followed by 5 individual support sessions), both given over 6 months. Participants will rate their weekly progress during treatment using a mobile-enhanced online platform. Family communication will be assessed in a laboratory interactional task at baseline and post-treatment. Independent evaluators will assess APS (primary outcome) and psychosocial functioning (secondary outcome) every 6 months over 18 months.ResultsWe hypothesize that, compared to enhanced care, FFT-CHR will be associated with greater improvements in APS and psychosocial functioning over 18 months. Secondarily, improvements in family communication over 6 months will mediate the relationship between treatment condition and primary and secondary outcomes over 18 months. The effects of FFT-CHR are predicted to be greater in individuals with higher baseline risk for psychosis conversion.ConclusionsResults of the trial will inform treatment guidelines for individuals at high risk for psychosis.
- Published
- 2022
43. North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description.
- Author
-
Addington, Jean, Liu, Lu, Brummitt, Kali, Bearden, Carrie E, Cadenhead, Kristin S, Cornblatt, Barbara A, Keshavan, Matcheri, Mathalon, Daniel H, McGlashan, Thomas H, Perkins, Diana O, Seidman, Larry J, Stone, William, Tsuang, Ming T, Walker, Elaine F, Woods, Scott W, and Cannon, Tyrone D
- Subjects
Humans ,Longitudinal Studies ,Prospective Studies ,Psychotic Disorders ,Adolescent ,North America ,Prodromal Symptoms ,Clinical high risk ,Methodology ,Psychosis ,Schizophrenia ,Prevention ,Clinical Research ,Mental Health ,Good Health and Well Being ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Psychiatry - Abstract
The North American Prodrome Longitudinal Study (NAPLS) is a consortium of nine programs focusing on youth at clinical high risk (CHR) for psychosis. Funded by the National Institute of Mental Health (NIMH), the sites are located at Emory University, Harvard University, University of Calgary, University of California at Los Angeles, at San Diego, and at San Francisco, University of North Carolina Chapel Hill, Yale University, and Zucker Hillside Hospital. There have been two previous endeavors completed by this consortium, known as NAPLS-1 and NAPLS-2. This paper first offers an overview of the methodology of the third phase of the NAPLS consortium, the second five-year prospective study NAPLS-3, which aims to determine mechanisms of the development of psychosis. In addition, we report on the ascertainment and demographics of the 710 CHR participants in NAPLS-3.
- Published
- 2022
44. Screening for the at-risk mental state in young people : identifying psychosis-risk with the Prodromal Questionnaire-16 (PQ-16)
- Author
-
Howie, Clare, Mulholland, Ciaran, Davidson, Gavin, and Shannon, Ciaran
- Subjects
psychosis ,at-risk mental state ,screening ,prodromal symptoms ,Prodromal Questionnaire-16 - Abstract
Background: Psychosis can be debilitating for those affected and can have impacts on wider society and early identification and intervention for psychosis can improve outcomes for individuals with psychotic disorders. Research over the last century has shown that there is a prodromal period before the onset of psychotic disorders and this has become a target for researchers and clinicians to identify this prodromal period and intervene at this point. The at-risk mental state is a concept developed in the 1990s which described subthreshold psychotic symptoms and aimed to identify those at-risk of psychosis and offer intervention. Clinics can offer assessment and intervention for those referred to their services, but further work needs to be done to identify those who are not help-seeking but still distressed by attenuated symptoms. Screening measures for the at-risk mental state may provide a means of reducing time for assessment and the use of screening in non-clinical settings may identify more individuals at-risk of psychosis, and at an earlier stage. Aims and methods: This thesis is comprised of four original studies to examine the use of screening in non-clinical settings and the suitability of a specific screening measure for the at-risk mental state: The Prodromal Questionnaire-16 (PQ-16). Chapter 3 is a systematic review conducted to identify what screening has been conducted within educational settings, how screening has been conducted, particularly what screening measures have been implemented, and to explore the need for further research within this area. Two factor analytic studies were conducted to examine the structure of the PQ-16 in two non-clinical populations. Chapter 4 examined the structure of the PQ-16 in a sample (N=1045) who completed the study through Amazon's Mechanical Turk, with an average age of 27 years. Chapter 5 examined the structure of the PQ-16 in a sample (n=1165) who completed the PQ-16 as part of the Northern Ireland Youth Wellbeing Survey, with an average age of 15 years. It also determined if there were any differences in the structure of this screening measure between these two cohorts. Chapter 6 aimed to examine the association between adverse and benevolent childhood experiences and attenuated psychotic symptoms in a youth population sample (n=1165), using the PQ-16 to identify attenuated symptoms. This is to identify if there are certain experiences that are present in those who experience attenuated psychotic symptoms and clinicians and researchers should be aware of when screening for these symptoms. Results: The systematic review provided evidence that screening for the ARMS has been conducted within educational settings and the rate of individuals at-risk of psychosis in these settings vary. For clinicians and researcher using the PQ-16 in educational settings, the use of different cut-off scoring for follow-up assessment should be considered to avoid a high rate of false positives. Chapter 4 identified a three-factor model representing perceptual abnormalities/hallucinations, unusual thought content, and negative symptoms appeared to be a better fit for the data in this study. Chapter 5 indicated a two-factor structure in the PQ-16 in this study. Factor 1 represented hallucinations and factor 2 represented perplexity/anxiety. This highlighted that there was a difference in how the PQ-16 is structured across two age groups in non-clinical settings. Chapter 6 identified that prodromal symptoms as identified by the PQ-16 were associated with childhood abuse and neglect, and benevolent childhood experiences were negative predictor of symptoms. Conclusion: The aim of this thesis was to examine the role of screening for psychosis prevention, specifically the use of the Prodromal Questionnaire-16 and its suitability for screening for the at-risk mental state. The use of the PQ-16 as a screening measure in non-clinical settings is appropriate but its use should be adapted depending on the population due to the potential differences in structure and the need for differing cut-off scores. The co-occurrence of childhood adversities with prodromal symptoms should be considered when researching the at-risk mental state in non-clinical settings.
- Published
- 2022
45. MBCT and CBT for Youth at High Risk for Mood and Psychotic Disorders: a Randomized Controlled Trial
- Author
-
David J. Miklowitz, Ph.D., Principal Investigator
- Published
- 2022
46. Risk stratification for treating people at ultra-high risk for psychosis: A cost-effectiveness analysis.
- Author
-
Ologundudu, Olajumoke M., Palaniyappan, Lena, Cipriano, Lauren E., Wijnen, Ben F.M., Anderson, Kelly K., and Ali, Shehzad
- Subjects
- *
COST effectiveness , *PSYCHOSES , *ECONOMIC models , *COST benefit analysis , *AT-risk people - Abstract
People who are at ultra-high risk (UHR) for psychosis receive clinical care with the aim to prevent first-episode psychosis (FEP), regardless of the risk of conversion to psychosis. An economic model from the Canadian health system perspective was developed to evaluate the cost-effectiveness of treating all with UHR compared to risk stratification over a 15-year time horizon, based on conversion probability, expected quality-of-life and costs. The analysis used a decision tree followed by a Markov model. Health states included: Not UHR, UHR with <20 % risk of conversion to FEP (based on the North American Prodrome Longitudinal Study risk calculator), UHR with ≥20 % risk, FEP, Remission, Post-FEP, and Death. The analysis found that: risk stratification (i.e., only treating those with ≥20 % risk) had lower costs ($1398) and quality-adjusted life-years (0.055 QALYs) per person compared to treating all. The incremental cost-effectiveness ratio for 'treat all' was $25,448/QALY, and suggests treating all may be cost-effective. The model was sensitive to changes to the probability of conversion. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. Identifying prodromal symptoms at high specificity for Parkinson's disease.
- Author
-
Jackson, Holly, Anzures-Cabrera, Judith, Simuni, Tanya, Postuma, Ronald B., Marek, Kenneth, and Pagano, Gennaro
- Subjects
SCIENTIFIC observation ,CONFIDENCE intervals ,CONSTIPATION ,SPEECH disorders ,MOVEMENT disorders ,RISK assessment ,PARKINSON'S disease ,AFFECTIVE disorders ,DESCRIPTIVE statistics ,RESEARCH funding ,ODDS ratio ,SENSITIVITY & specificity (Statistics) ,DISEASE risk factors ,SYMPTOMS - Abstract
Introduction: To test drugs with the potential to prevent the onset of Parkinson's disease (PD), it is key to identify individuals in the general population at high risk of developing PD. This is often difficult because most of the clinical markers are non- specific, common in PD but also common in older adults (e.g., sleep problems). Objective: We aimed to identify the clinical markers at high specificity for developing PD by comparing individuals with PD or prodromal PD to healthy controls. Methods: We investigated motor and non-motor symptoms (Movement Disorder Society Unified Parkinson's Disease Rating Scale Part 1 and 2 items) in 64 prodromal PD and 422 PD individuals calculating the odds ratios, adjusting for age and gender, for PD and prodromal PD versus 195 healthy controls. Symptoms at high specificity were defined as having an adjusted odds ratio ≥ 6. Results: Constipation had an adjusted odds ratio, 6.14 [95% CI: 2.94--12.80] showing high specificity for prodromal PD, and speech difficulties had an adjusted odds ratio, 9.61 [95% CI: 7.88--48.81] showing high specificity for PD. The proportion of participants showing these specific markers was moderate (e.g., prevalence of constipation was 43.75% in prodromal PD, and speech difficulties was 33.89% in PD), suggesting these symptoms may make robust predictors of prodromal PD and PD, respectively. Discussion: Clinical markers at high specificity for developing PD could be used as tools in the screening of general populations to identify individuals at higher risk of developing PD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Individualized Prediction of Prodromal Symptom Remission for Youth at Clinical High Risk for Psychosis.
- Author
-
Worthington, Michelle A, Addington, Jean, Bearden, Carrie E, Cadenhead, Kristin S, Cornblatt, Barbara A, Keshavan, Matcheri, Mathalon, Daniel H, McGlashan, Thomas H, Perkins, Diana O, Stone, William S, Tsuang, Ming T, Walker, Elaine F, Woods, Scott W, and Cannon, Tyrone D
- Subjects
Serious Mental Illness ,Mental Health ,Clinical Research ,Pediatric ,Brain Disorders ,Prevention ,Good Health and Well Being ,Adolescent ,Adult ,Child ,Disease Progression ,Female ,Humans ,Longitudinal Studies ,Machine Learning ,Male ,Prodromal Symptoms ,Psychotic Disorders ,Remission Induction ,Risk Assessment ,remission ,clinical high risk ,schizophrenia ,psychosis ,risk prediction ,machine learning ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Psychiatry - Abstract
The clinical high-risk period before a first episode of psychosis (CHR-P) has been widely studied with the goal of understanding the development of psychosis; however, less attention has been paid to the 75%-80% of CHR-P individuals who do not transition to psychosis. It is an open question whether multivariable models could be developed to predict remission outcomes at the same level of performance and generalizability as those that predict conversion to psychosis. Participants were drawn from the North American Prodrome Longitudinal Study (NAPLS3). An empirically derived set of clinical and demographic predictor variables were selected with elastic net regularization and were included in a gradient boosting machine algorithm to predict prodromal symptom remission. The predictive model was tested in a comparably sized independent sample (NAPLS2). The classification algorithm developed in NAPLS3 achieved an area under the curve of 0.66 (0.60-0.72) with a sensitivity of 0.68 and specificity of 0.53 when tested in an independent external sample (NAPLS2). Overall, future remitters had lower baseline prodromal symptoms than nonremitters. This study is the first to use a data-driven machine-learning approach to assess clinical and demographic predictors of symptomatic remission in individuals who do not convert to psychosis. The predictive power of the models in this study suggest that remission represents a unique clinical phenomenon. Further study is warranted to best understand factors contributing to resilience and recovery from the CHR-P state.
- Published
- 2022
49. Life Event Stress and Reduced Cortical Thickness in Youth at Clinical High Risk for Psychosis and Healthy Control Subjects
- Author
-
Aberizk, Katrina, Collins, Meghan A, Addington, Jean, Bearden, Carrie E, Cadenhead, Kristin S, Cornblatt, Barbara A, Mathalon, Daniel H, McGlashan, Thomas H, Perkins, Diana O, Tsuang, Ming T, Woods, Scott W, Cannon, Tyrone D, and Walker, Elaine F
- Subjects
Clinical Research ,Prevention ,Pediatric ,2.1 Biological and endogenous factors ,2.3 Psychological ,social and economic factors ,Aetiology ,Adolescent ,Female ,Humans ,Longitudinal Studies ,Male ,Prodromal Symptoms ,Psychotic Disorders ,Risk Factors ,Stress ,Psychological ,Clinical high risk ,Cortical thickness ,Environment ,Life stress ,Neuromaturation ,Psychosis - Abstract
BackgroundA decline in cortical thickness during early life appears to be a normal neuromaturational process. Accelerated cortical thinning has been linked with conversion to psychosis among individuals at clinical high risk for psychosis (CHR-P). Previous research indicates that exposure to life event stress (LES) is associated with exaggerated cortical thinning in both healthy and clinical populations, and LES is also linked with conversion to psychosis in CHR-P. To date, there are no reports on the relationship of LES with cortical thickness in CHR-P. This study examines this relationship and whether LES is linked with cortical thinning to a greater degree in individuals at CHR-P who convert to psychosis compared with individuals at CHR-P who do not convert and healthy control subjects.MethodsControlling for age and gender (364 male, 262 female), this study examined associations between LES and baseline cortical thickness in 436 individuals at CHR-P (375 nonconverters and 61 converters) and 190 comparison subjects in the North American Prodrome Longitudinal Study.ResultsFindings indicate that prebaseline cumulative LES is associated with reduced baseline cortical thickness in several regions among the CHR-P and control groups. Evidence suggests that LES is a risk factor for thinner cortex to the same extent across diagnostic groups, while CHR-P status is linked with thinner cortex in select regions after accounting for LES.ConclusionsThis research provides additional evidence to support the role of LES in cortical thinning in both healthy youth and those at CHR-P. Potential underlying mechanisms of the findings and implications for future research are discussed.
- Published
- 2022
50. Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney
- Author
-
Sexton, Claire E, Anstey, Kaarin J, Baldacci, Filippo, Barnum, CJ, Barron, Anna M, Blennow, Kaj, Brodaty, Henry, Burnham, Samantha, Elahi, Fanny M, Götz, Jürgen, Jeon, Yun‐Hee, Koronyo‐Hamaoui, Maya, Landau, Susan M, Lautenschlager, Nicola T, Laws, Simon M, Lipnicki, Darren M, Lu, Hanzhang, Masters, Colin L, Moyle, Wendy, Nakamura, Akinori, Pasinetti, Giulio Maria, Rao, Naren, Rowe, Christopher, Sachdev, Perminder S, Schofield, Peter R, Sigurdsson, Einar M, Smith, Kate, Srikanth, Velandai, Szoeke, Cassandra, Tansey, Malú G, Whitmer, Rachel, Wilcock, Donna, Wong, Tien Y, Bain, Lisa J, and Carrillo, Maria C
- Subjects
Biomedical and Clinical Sciences ,Biological Psychology ,Clinical Sciences ,Neurosciences ,Psychology ,Dementia ,Neurodegenerative ,Acquired Cognitive Impairment ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Alzheimer's Disease ,Aging ,Brain Disorders ,Behavioral and Social Science ,Neurological ,Alzheimer Disease ,Australia ,Biomarkers ,Biomedical Research ,Cognitive Dysfunction ,Disease Progression ,Humans ,Life Style ,Positron-Emission Tomography ,Prodromal Symptoms ,Alzheimer&apos ,s ,dementia ,behavioral symptoms ,biomarkers ,prevention ,Alzheimer's ,Geriatrics ,Clinical sciences ,Biological psychology - Abstract
The Alzheimer's Association International Conference held its sixth Satellite Symposium in Sydney, Australia in 2019, highlighting the leadership of Australian researchers in advancing the understanding of and treatment developments for Alzheimer's disease (AD) and other dementias. This leadership includes the Australian Imaging, Biomarker, and Lifestyle Flagship Study of Ageing (AIBL), which has fueled the identification and development of many biomarkers and novel therapeutics. Two multimodal lifestyle intervention studies have been launched in Australia; and Australian researchers have played leadership roles in other global studies in diverse populations. Australian researchers have also played an instrumental role in efforts to understand mechanisms underlying vascular contributions to cognitive impairment and dementia; and through the Women's Healthy Aging Project have elucidated hormonal and other factors that contribute to the increased risk of AD in women. Alleviating the behavioral and psychological symptoms of dementia has also been a strong research and clinical focus in Australia.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.